Table 4 FDA-approved targeted therapy for BRAF mutations
From: Emerging therapeutic agents for advanced non-small cell lung cancer
Drug | Month/year | Indication | Comments |
|---|---|---|---|
Dabrafenib+trametinib | June/2017 | Metastatic BRAF V600E+ NSCLC | Â |
From: Emerging therapeutic agents for advanced non-small cell lung cancer
Drug | Month/year | Indication | Comments |
|---|---|---|---|
Dabrafenib+trametinib | June/2017 | Metastatic BRAF V600E+ NSCLC | Â |